Journal article
The Fanconi anemia ubiquitin E3 ligase complex as an anti-cancer target
MF Sharp, R Bythell-Douglas, AJ Deans, W Crismani
Molecular Cell | Published : 2021
Abstract
Agents that induce DNA damage can cure some cancers. However, the side effects of chemotherapy are severe because of the indiscriminate action of DNA-damaging agents on both healthy and cancerous cells. DNA repair pathway inhibition provides a less toxic and targeted alternative to chemotherapy. A compelling DNA repair target is the Fanconi anemia (FA) E3 ligase core complex due to its critical—and likely singular—role in the efficient removal of specific DNA lesions. FA pathway inactivation has been demonstrated to specifically kill some types of cancer cells without the addition of exogenous DNA damage, including cells that lack BRCA1, BRCA2, ATM, or functionally related genes. In this per..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
We are grateful to Hannah Fluhler, Agata Smogorzewska, and Andrew Lloyd for helpful comments on the manuscript. M.F.S. and W.C. receive funding from the Bourne Foundation. R.B.-D. is supported by a fellowship (IIRS-19-017) from the National Breast Cancer Foundation. W.C. receives a Career Development Fellowship from the Australian National Health and Medical Research Council (GNT1129757). This work is supported by grants from the Australian National Health and Medical Research Council (GNT1185387 to W.C., GNT1181110 to A.J.D., and GNT1156343 to W.C. and A.J.D.).